PubMed Health⌕ Search

Biomedical subjects

C Doutremepuich

Publications and source records attributed to C Doutremepuich.

98 records · Page 6Linked to original sources

[Artificial blood: the future of blood transfusion? II. Blood substitutes other than hemoglobin solutions].

Part 2 discusses the state-of-the-art in oxygen-transporting blood substitutes other than hemoglobin solutions (Part 1); these are the fluorocarbon emulsions, the hemoglobin liposomes and other products such as oxygen-chelating agents. The substitutes reviewed here may play an important future role; before then, their stability, ease of administration, innocuity and value in human clinical medicine must be ensured.

Animals↗

[Hemostasis].

Explore the source record for details and available documents.

Blood Coagulation Factors↗

[Experimental models of venous thrombosis].

Various experimental models have been developed in order to more clearly understand deep vein thrombosis, the mechanisms involved and its treatment. These models are based on venous stasis, either alone or combined with the injection of thrombogenic substances or endothelial lesions. Other models only use endothelial lesions. Thrombogenic substances are mostly composed of activated factor X or thrombin, which raises the problem of purity of the substances and determination of the antithrombotic activities of the substance tested, especially heparin and hirudin and their derivatives, and consequently their efficacy. Endothelial lesions can be induced by chemical, physical or electrical agents or by repeated application of clamps, or cellular crushing. These models result in the formation of various forms of venous thrombus. The development and improvement of experimental models is very important in every case. Experimental models of thrombosis constitute the best tool for the study of thrombosis, in which many points remain to be elucidated. They also allow the study and development of various antithrombotic substances the improvement of their efficacy. These models must be validated, standardized, reproductible and in agreement with local legislation in each country.

Animals↗

[Difficulties of assessing postoperative pulmonary embolisms. Risks of meta-analysis from clinical trials].

During the 1970's, several large clinical trials have shown low dose subcutaneous heparin to be effective in the prevention of post-operative lethal pulmonary embolism. These claims have been widely accepted mainly because the selected main criterion was effectively pulmonary embolism. To-date, this criterion appears to be poorly reliable clinically and ethically unacceptable due to lethal risk. In practically all recent trials with low molecular weight heparin fractions in this indication, the main criterion has been prevention of deep vein thrombosis and not of pulmonary embolism. This is why, among other reasons exposed in this study, it would be hazardous to perform any meta-analysis related to pulmonary embolism from trials which have not been designed for this purpose.

Drug Evaluation↗